EU collaborative STREAM
for leukemia patients

IMPACT-AML builds a pioneering research framework for Relapsed or Refractory Acute Myeloid Leukemia, unifying patients, clinicians, and researchers across Europe and beyond. At its core, STREAM enables real-world evidence integration and supports pragmatic clinical trials, laying the foundation for future patient-centric treatments and advancing collaborative innovation in AML care.

About the project
Browse the brochure

DISCOVER IMPACT-AML

OUR MISSION

We are committed to transforming the treatment landscape of R/R AML by developing an inclusive research framework that ensures no patient is left behind. Through data harmonization, biobanking standardization, and the first cutting-edge clinical trials, we aim to generate robust scientific evidence that will drive better and standardise therapies across the EU, ensuring equitable access to care for all AML patients.

WHAT IS R/R AML?

Relapsed/Refractory Acute Myeloid Leukemia is a severe form of leukemia that returns after remission (relapse) or resists the initial treatment (refractory). Its complexity, therapy resistance, and lack of standardized care make it hard to treat. Access to care can vary due to limited treatment options, hospital expertise and infrastructure, socio-economic factors, creating disparities. Ongoing research and therapeutics solutions aim to improve survival and bridge patients and caregivers to enhance life prospects.

Find out more

THE “STREAM” PLATFORM

STREAM is an open collaborative platform designed to collect essential patient data on R/R AML across clinical centers.  By enabling clinicians to securely record a minimum dataset, STREAM helps identify patients for current and future clinical trials, fostering research and improving treatment options. It enables real-world evidence generation and innovative research through collaboration, improving outcomes and advancing treatment.

Find out more

EMBRACE OUR MISSION

Join IMPACT-AML and be part of a collaborative Network of haematology centres and researchers dedicated to improving care for R/R AML patients. Your contribution is key to expanding access to innovative clinical trials, generating real-world data, and shaping the future of AML research. Together, we can turn scientific progress into life-changing treatments.

HEMATOLOGISTS

Collaborate with the IMPACT-AML Consortium in feeding STREAM and create access to cutting-edge new clinical trials and innovative treatments for your patients. Work alongside European haematologists to shape patient-centered therapies, enhance treatment standards, create new collaborative research studies and drive advancements that improve both survival and quality of life.

Find out more

PHARMACEUTICAL COMPANIES

Partner with IMPACT-AML to revolutionize R/R AML treatment. Use STREAM to find an easy and fast tool to test therapies in real-world and clinical settings and collaborate with leading researchers. Together, we can advance innovation, improve patient care, and expand market access.

Find out more

News & Events

See all

“DIAGNOSIS AND TREATMENT” CLUSTER

IMPACT-AML is part of the EU Cancer Mission “Diagnosis and Treatment” Cluster, a network that brings together 12 projects funded by the Horizon Europe program that synergistically contribute to the EU Cancer Mission objective of improving tumour diagnosis and treatment and cancer patients’ quality of life during and beyond their cancer treatment.
The 12 projects — CARE1, DE-ESCALATE, IMPACT-AML, IMPORTANT, IntReALL 2020, LEGATO, LIVERATION5, PragmaTIL, PRIME-ROSE, Sagittarius, SALVOVAR e STREXIT2 — are organised in working groups within the Cluster, which address relevant transversal topics such as Data Management, Dissemination and Communication of Results, Research and Innovation, Citizen Engagement, and Addressing Inequalities.

Discover more